Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* The participant and/or participant's parent(s)/legal guardian(s) must provide written informed assent/consent prior to any protocol-related procedures being performed.~* The participant was \<18 years of age on the date of informed assent/consent.~* The participant had documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes.~* The participant had a spleen volume greater than or equal to (\>=) 5 multiples of normal (MN) measured by magnetic resonance imaging (MRI); participants who had partial splenectomy were allowed if the procedure was performed \>=1 year before screening and the residual spleen volume was \>=5 MN.~* The participant's height was -1 Z-score or lower.~* A negative serum pregnancy test in female participants of childbearing potential.~* Female participants of childbearing potential and male participants must be willing to practice true abstinence in line with their preferred and usual lifestyle or use 2 acceptable effective methods of contraception.~Exclusion criteria:~* The participant had received an investigational drug within 30 days before study enrollment.~* The participant had any of the following medical conditions:~* An active, serious, intercurrent illness.~* Active hepatitis B or hepatitis C infection.~* Infection with human immunodeficiency virus (HIV).~* Cirrhosis (determined by clinical evaluation).~* Significant cardiac disease (eg, clinically significant arrhythmia, moderate or severe pulmonary hypertension or valvular dysfunction, or \<40 percent (%) left ventricular ejection fraction by echocardiogram).~* Malignancy diagnosed within the previous 5 years (except basal cell carcinoma).~* Any other extenuating circumstance that can significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.~* The participant had acute or rapidly progressive neurological abnormalities.~* The participant was homozygous for SMPD1 gene mutations R496L, L302P, and fs330 or any combination of these 3 mutations.~* The participant had a delay of gross motor skills.~* The participant had a major organ transplant (eg, bone marrow, liver).~* The participant required use of invasive ventilatory support.~* The participant required use of noninvasive ventilatory support while awake and for greater than (\>)12 hours a day.~* The participant in the investigator's opinion, was unable to adhere to the requirements of the study.~* The participant had a platelet count \<60 × 10\^3/µL (based on the average of 2 screening samples obtained up to 24 hours apart).~* The participant had alanine aminotransferase or aspartate aminotransferase \>250 IU/L or total bilirubin \>1.5 mg/dL.~* The participant had an international normalized ratio (INR) \>1.5.~* The participant was unwilling or unable to abstain from ingesting alcohol the day before through 3 days after each infusion of olipudase alfa during the treatment period. Measuring alcohol concentration in blood was not required.~* The participant was scheduled during the study for in-patient hospitalization including elective surgery.~* The participant required medication(s) that may can decrease olipudase alfa activity (eg, fluoxetine, chlorpromazine; tricyclic antidepressants \[eg, imipramine, or desipramine\]).~* The participant was breast-feeding.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Olipudase alfa (Type: EXPERIMENTAL): Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).